Adjuvant Therapy in Pancreatic Cancer

被引:18
|
作者
Thomas, Amy [1 ]
Dajani, Khaled [1 ]
Neoptolemos, John P. [1 ]
Ghaneh, Paula [1 ]
机构
[1] Univ Liverpool, Div Surg & Oncol, Sch Canc Studies, Liverpool L69 3GA, Merseyside, England
关键词
Pancreatic cancer; Adjuvant chemotherapy; Meta-analysis; RANDOMIZED CONTROLLED-TRIAL; PHASE-III TRIAL; RADIATION-THERAPY; CURATIVE RESECTION; INTRAOPERATIVE RADIOTHERAPY; EXTENDED LYMPHADENECTOMY; IMPROVED SURVIVAL; ELECTRON-BEAM; UNITED-STATES; FOLINIC ACID;
D O I
10.1159/000320099
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Pancreatic cancer is one of the major causes of cancer death in Europe with a 5-year survival rate of less than 5%. Although surgery cannot guarantee a cure, the 5-year survival does improve to around 10% following resection and increases to 20-30% with adjuvant chemotherapy. The European Study Group for Pancreatic Cancer (ESPAC) 1 trial was the first adequately powered, randomized study to assess chemoradiotherapy (CRT), concurrent with 5-fluorouracil (5-FU) and chemotherapy [5-FU/folinic acid (FA)] in resected pancreatic cancer. There was a survival benefit for adjuvant chemotherapy, but not for adjuvant CRT. Adjuvant CRT also did not improve survival in the EORTC multicenter prospective randomized trial by Klinkenbijl et al. (1999). The phase 3 RTOG 9704 trial compared pre- and postchemoradiation gemcitabine to pre-and postchemoradiation 5-FU. Overall there was no difference in overall survival between the 2 arms. Adjuvant gemcitabine significantly improved disease-free survival and later overall survival compared to surgery alone in the CONKO-001 randomized trial. The ESPAC-3(v2) trial compared adjuvant gemcitabine versus 5-FU/FA. The final 2-year analysis demonstrated median survival from resection of patients treated with 5-FU/FA was 23.0 months (95% CI: 21.1, 25.0) and 23.6 months (95% CI: 21.4, 26.4) for patients treated with gemcitabine. Further randomized studies will assess the role of adjuvant combination chemotherapy (ESPAC-4). The key to the future of adjuvant therapy in pancreatic cancer will be the identification of novel and effective agents, and better biomarker technology underpinned by translational research which will inform the design of future trials. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:684 / 692
页数:9
相关论文
共 50 条
  • [1] Adjuvant Therapy of Pancreatic Cancer
    Sharma, Charu
    Horowitz, David
    Chabot, John
    Saif, Muhammad Wasif
    [J]. JOURNAL OF THE PANCREAS, 2011, 12 (04): : 343 - 346
  • [2] Adjuvant Therapy of Pancreatic Cancer
    Chaulagain, Chakra P.
    Ng, John
    Wazer, David
    Saif, Muhammad Wasif
    [J]. JOURNAL OF THE PANCREAS, 2012, 13 (04): : 349 - 353
  • [3] Adjuvant therapy in pancreatic cancer
    Ghaneh, P
    Slavin, J
    Sutton, R
    Hartley, M
    Neoptolemos, JP
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2001, 7 (04) : 482 - 489
  • [4] Adjuvant therapy of pancreatic cancer
    Hilbig, Andreas
    Oettle, Helmut
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (04) : 485 - 491
  • [5] Adjuvant Therapy for Pancreatic Cancer
    Paula Ghaneh
    Anthony Kawesha
    Nathan Howes
    Lucie Jones
    John P. Neoptolemos
    [J]. World Journal of Surgery, 1999, 23 : 937 - 945
  • [6] Pancreatic cancer–Adjuvant therapy
    Asma Sultana
    John Neoptolemos
    Paula Ghaneh
    [J]. Oncology and Translational Medicine, 2007, (02) : 170 - 175
  • [7] Adjuvant therapy of pancreatic cancer
    Willett, Christopher G.
    Czito, Brian G.
    Bendell, Johanna C.
    [J]. CANCER JOURNAL, 2007, 13 (03): : 185 - 191
  • [8] Adjuvant therapy in pancreatic cancer
    Paula Ghaneh
    John Slavin
    Robert Sutton
    Mark Hartley
    John P Neoptolemos
    [J]. World Journal of Gastroenterology, 2001, (04) : 482 - 489
  • [9] Adjuvant therapy in pancreatic cancer
    Owain Peris Jones
    James Daniel Melling
    Paula Ghaneh
    [J]. World Journal of Gastroenterology, 2014, (40) : 14733 - 14746
  • [10] Adjuvant therapy for pancreatic cancer
    Aung, Kyaw L.
    Smith, David B.
    Neoptolemos, J. P.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2533 - 2541